@article {2243,
	title = {Altering pyridinone N-substituents to optimise activity as potential prodrugs for Alzheimer{\textquoteright}s disease},
	journal = {Dalton Transactions},
	number = {45},
	year = {2008},
	note = {ISI Document Delivery No.: 371METimes Cited: 5Cited Reference Count: 29Scott, Lauren E. Page, Brent D. G. Patrick, Brian O. Orvig, Chris},
	pages = {6364-6367},
	type = {Article},
	abstract = {Selective design modifications of specifically substituted 3-hydroxy-4(1H)-pyridinones show possibly advantageous ring freedom while maintaining metal-binding ability and antioxidant capacity, moving toward an efficient potential treatment for Alzheimer{\textquoteright}s disease.},
	keywords = {aluminum, BLOOD-BRAIN-BARRIER, COMPLEXES, DISORDERS, DIVALENT, IRON CHELATORS, PENETRATION, STABILITIES, therapy, TRIVALENT METAL-IONS},
	isbn = {1477-9226},
	url = {<Go to ISI>://000260834600005},
	author = {Scott, L. E. and Page, B. D. G. and Patrick, B. O. and Orvig, Chris}
}
@article {2952,
	title = {PHARMACOKINETICS OF ALUMINUM 3-HYDROXYPYRIDIN-4-ONE COMPLEXES - IMPLICATIONS FOR ALUMINUM REDISTRIBUTION SUBSEQUENT TO CHELATION-THERAPY},
	journal = {Toxicology},
	volume = {92},
	number = {1-3},
	year = {1994},
	note = {ISI Document Delivery No.: PK035Times Cited: 14Cited Reference Count: 34},
	month = {Sep},
	pages = {193-202},
	type = {Article},
	abstract = {The pharmacokinetics of selected aluminum-hydroxypyridinone (Al-HP) complexes were determined in rats to better understand the relationship between their disposition and elimination parameters and the safety of HPs in the chelation therapy of Al intoxication. Five complexes were administered as i.v. bolus doses of Al-HP (0.25 mmol/kg Al-0.75 mmol/kg HP). The Al-HP steady state volumes of distribution ranged from 220 to 871 ml/kg, suggesting that each complex distributed out of the vascular compartment (which should have been approximate to 65 ml/kg). Systemic clearances ranged from 189 to 906 ml/h per kg. Elimination half-lives (t(1/2)) and mean residence times ranged from 0.36 to 0.84 and 0.52 to 1.20 h, respectively. The Al-CP20 complex had a short t(1/2) and a midrange volume of distribution. It demonstrated no apparent toxicity, whereas myoclonic seizures were observed after Al-CP22, Al-CP24 and Al-CP94 administration. The most appropriate choice for Al chelation among the HPs tested may be CP20. Characterization of the distribution and elimination of Al-HP complexes improves the understanding of potential toxicity that may be associated with HP therapy of Al intoxication.},
	keywords = {3-HYDROXY-4-PYRIDINONES, 3-HYDROXYPYRIDIN-4-ONES, aluminum, ALUMINUM CHELATION, ALUMINUM TOXICITY, CHELATION, DESFERRIOXAMINE, ENCEPHALOPATHY, gallium, INTOXICATION, INVITRO, IRON CHELATORS, OCULAR TOXICITY, pharmacokinetics, RENAL-FAILURE, SUBCUTANEOUS DEFEROXAMINE},
	isbn = {0300-483X},
	url = {<Go to ISI>://A1994PK03500015},
	author = {Allen, D. D. and Orvig, Chris and Yokel, R. A.}
}
